Bevacizumab biosimilar - AskGene Pharma

Drug Profile

Bevacizumab biosimilar - AskGene Pharma

Alternative Names: ASK B1202

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AskGene Pharma
  • Developer AskGene Pharma; Jiangsu Aosaikang Pharmaceutical
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Apr 2017 Jiangsu Aosaikang Pharmaceutical plans a phase I trial in Healthy volunteers (IV, Infusion) (NCT03115762)
  • 15 Nov 2016 Preclinical trials in Cancer in USA (IV) before November 2016
  • 15 Nov 2016 Pharmacodynamics data from preclinical trials in Cancer released by Jiangsu Aosaikang Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top